Cathie Wood Sees 20% Returns After 'Unbelievable' 2020

Cathie always predict the future!

Conveniently forgotten or redefinition?

Everybody has an opinion about the future. But itā€™s quite different from saying a crash will happen on such and such date and by how much.

IMHO is 100 feet laughing at 1000 feet.

A scale of 10x.

Good. So you are agreeing toā€¦

:wink: Was talking about her, not Panda, not Rob, not John, not Jane, ā€¦

Donā€™t know what ā€œlosing her touchā€ means. Did not expect anyone to get everything right. Anyway, I donā€™t have any money invested in her funds. I just like to read and watch her research. Some I agree some I donā€™t. But agreeing or not she has some unique takes. Thatā€™s what makes it interesting.

This Permabear predicts catastrophic collapse
He is probably trying to sell something. I donā€™t care.

Legendary Investor Jim Rogers Warns: Your Retirement May Not Survive The Coming Dollar Collapseā€¦

Jim Rogers here, with an urgent warning for American retirees and those hoping to retire soonā€¦

The coming bear market in stocks will be more catastrophic than any downturn Iā€™ve lived through to date.

Worse than 1987ā€¦ the Dot-Com Crashā€¦ and even the 2008-2009 collapse.

Weā€™ve accumulated so much debt as a country that I believe we may actually be looking at the ā€œlast gaspā€ of the US dollar.

Yes, I know many assets are at all-time highs. I have eyes.

But my decades of experience as an investor let me see things you might not ā€“ and these bubbly markets are a veritable cauldron of trouble.

Excesses always lead to problems ā€“ and the way Bidenā€™s people want to spend, excesses are the name of the game.

With so much debtā€¦ so much excess at every levelā€¦ America wonā€™t be able to keep the dollar in place as the worldā€™s reserve currency.

And once we fall from that pedestal, itā€™s a long, long way downā€¦

Maybe ā€“ if you could hold on long enough ā€“ your portfolio would recover.

Except at 80, I know I donā€™t have that kind of time left. And I suspect you donā€™t eitherā€¦

Thatā€™s why Iā€™d like to encourage you to take action promptly to protect your wealth from the coming calamity.

How?

Collapse of dollar = Mooning bitcoin, gold and stock market.

Protect which one? Cash in dollar or stocks?

RE should be able to protect vs both :slight_smile: Except may be RE in Bay Area which is RSU (used to be EO) driven.

Anyhoo, just like Jim Roger, I has RE in SG :slight_smile: Hedge vs dollar depreciation :grinning:

He is a dilettante and a fraud.

Does not Jim Rogers sell some newsletters and investment advise at damn cheap price?

Cathie is back.

2 Likes

Skillz (SKLZ)

Skillz (SKLZ) traded up 27% on Wednesday after announcing an agreement to acquire Aarki, an adtech demand-side platform (DSP), for $150 million in cash and stock. Aarki engages in more than 5 trillion advertising auctions monthly with machine learning algorithms and data engines that help advertisers maximize customer reach and acquisition. Given Aarkiā€™s exposure to the UK, India, and South Korea, this strategic acquisition should accelerate Skillzā€™s international expansion goals. Lessening its dependence on third-party DSPs to reach new users, we believe the acquisition also should lower Skillzā€™ user acquisition costs and bolster the monetization of existing monthly active users (MAUs). Skillz is a leading mobile games platform that enables competitive esports. Leveraging its patented match-making technology, Skillz hosts billions of casual esports tournaments worldwide each year.

DocuSign (DOCU)

DocuSign (DOCU) traded up 19% on Friday after reporting strong earnings, surpassing expectations on both revenue and earnings and raising guidance for the second quarter and fiscal year. The company appears to be gaining traction in international markets and, although its Agreement Cloud offering still is in early stages of adoption, we remain confident that the COVID-induced transition to electronic agreements is not a temporary shift. Additions to the management team and clear strategic roadmaps have bolstered our confidence in the company. DocuSign offers cloud-based solutions for e-signature and related workflow automation, AI-enabled analytics, and lifecycle management.

Appleā€™s Annual Developer Conference Featured Some Notable Software and Service Updates

By Frank Downing
Analyst

This week, Appleā€™s World Wide Developer Conference kicked off with a jam-packed keynote featuring [a host of software and services updates. A common thread throughout the event was an emphasis on enabling Apple users to share data and experiences seamlessly throughout its ecosystem, all with privacy in mind.

  • SharePlay, an open API for synchronous content streaming, will enable users to listen to Apple Music or watch a show from HBO Max together with family and friends on a FaceTime call. Combined with Spatial Audio call scheduling and enhanced sharing features in iMessage, the new service will make communication on an Apple device more immersive and convenient.
  • In a push to address the digital identity problem and eliminate the need for physical wallets, Apple announced Digital ID, a digital copy of a userā€™s driverā€™s license or state ID, which the TSA intends to adopt. Apple could leverage this digital identity to reduce the friction in the authentication for apps and services.
  • Apple Health users will be able to share data like activity levels, sleep quality, and heart rates with their physicians and loved ones. This data could inform treatment decisions and alert family members to changes in health associated with irregular heartbeats and accidental falls, among many others.

Combined with new privacy features like on-device voice recognition and IP Address hiding, we believe each of these new services is likely to increase the Appleā€™s ecosystem stickiness as the social economyā€™s privacy-first player.

Is the FDA Becoming More Flexible in Drug Approvals?

By Ali Urman
Analyst

This week, the U.S. Food and Drug Administration (FDA) approved Biogenā€™s Aducanumab, a drug targeting amyloid plaque buildup in the brains of Alzheimerā€™s patients. As many families know all too well, Alzheimerā€™s is a devastating disease during which patients can lose both their memories and their abilities to perform daily tasks. According to the Center for Disease Control and Prevention (CDC), the number of people aged 65+ suffering from Alzheimerā€™s disease in the US will nearly triple during the next 50 years, from an estimated 5.8 million people today to 14 million in 2060.

The approval of Aducanumab was surprising for several reasons:

  • Broad Label: Doctors will be able to prescribe Aducanumab for any Alzheimerā€™s patients whether they suffer from mild or severe forms of the disease. This broad label was a surprise because the clinical trial included only patients suffering from a mild form of Alzheimerā€™s.
  • Cost: Aducanumab will cost $56,000 annually, a high sticker price given its low efficacy.
  • Toxicity: In its approval, the FDA seemed to place little to no emphasis on toxicity, which is puzzling because Alzheimerā€™s patients will have difficulty communicating ill effects to their families and care givers.
  • Clinical Benefit: Biogen will have nine years to complete the trial and demonstrate that Aducanumab delivers clinical benefit.
  • Imaging Requirements: By the end of their first year on Aducanumab, patients will have to undergo an MRI instead of a positron emission tomography (PET) scan to confirm beta-amyloid, the drugā€™s target.
  • Advisors: Three of the nine advisors on the Peripheral and Central Nervous System Drugs Advisory Committee - Aaron Kesselheim, Joel Perlmutter, and David Knopman ā€“ stepped down following the approval.

If the FDA seems to be approving therapeutic agents targeted at diseases with high unmet needs before confirmatory trials end, we believe the value of other such therapies showing little clinical efficacy could be much higher than most investors expect.

Is Facebookā€™s Smartwatch an Augmented Reality Device in Disguise?

By Nicholas Grous
Analyst

This week Facebook announced that it will launch a smartwatch next summer. According to several reports, the $400 smartwatch will feature two cameras and LTE connectivity.

So, why is the worldā€™s largest social media company entering the highly competitive smartwatch space? In our view, the answer lies in Facebookā€™s ambitions to lower its dependence on Apple and control the next mobile computing platform ā€“ augmented reality (AR). Apparently, Facebook believes a wrist device will be the interface for AR.

Why the wrist? Well, according to Facebook, ā€œItā€™s located right next to the primary instruments you use to interact with the world ā€” your hands.ā€

With a device at the wrist, electromyography sensors first will intercept the motor nerve signals that travel from the brain to the hand and then translate and relay that data to AR glasses, giving users the ability to control their new augmented reality with simple hand gestures. This demo shows how this tech works - watch!

While we do not expect the first few iterations of Facebookā€™s smartwatch to include this tech, the two projects probably will merge over time. If so, the future of mobile computing could be a pair of glasses and a watch, not a mobile phone.

1 Like

Need to read to realize these implications? Very slow. I have mentioned these moons ago.

Two weeks old video but still holds up pretty well. Lumber price then was $1,300 and now itā€™s $900. Rampant inflation right?

Lumber was $300 a year ago. Still a long way to go downā€¦ gas is near $5 in many CA cities. Beef prices have doubled at Costco. McDonalds prices have doubled in two years. Napa Wine is ridiculously priced. My rents are double what they were just 3 years ago. Nobody will work for less than $25/hr. I just turned down a project that would cost double what I had figured.

1 Like

@Elt1

@manch doesnā€™t understand trend. As far as he is concerned, lower than ATH is decline.